Loading...
XHKG
6821
Market cap8.99bUSD
Oct 09, Last price  
155.10HKD
1D
-4.85%
1Q
27.24%
IPO
-41.31%
Name

Asymchem Laboratories Tianjin Co Ltd

Chart & performance

D1W1MN
XHKG:6821 chart
P/E
38.89
P/S
6.60
EPS
3.40
Div yield, %
0.74%
Shrs. gr., 5y
1.78%
Rev. gr., 5y
16.29%
Revenues
6.67b
+14.91%
405,691,300424,399,200542,757,600716,207,200830,607,6941,103,194,9511,423,033,4121,834,877,6232,459,985,5333,136,724,0004,632,121,00010,230,186,0007,825,190,2975,804,657,3366,670,181,013
Net income
1.13b
+19.35%
65,372,50060,251,40074,729,500101,791,600153,545,029252,735,205341,287,662428,295,479553,863,843719,742,0001,069,273,9993,301,635,0002,268,810,446948,950,0381,132,569,775
CFO
1.41b
+12.22%
25,883,50034,384,900105,917,363127,045,751256,994,132278,355,646196,400,310415,060,930600,867,843569,291,589113,150,1213,286,910,7053,549,728,3831,254,337,0141,407,585,059
Dividend
Jun 25, 20261.49537 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.

Key people

Rui Yang
Co-Chief Executive Officer, Executive Director · since 2022
Chief Financial Officer, Chief Operating Officer, Executive Director · since 2024
Chaoyong Chen
Executive Vice President · since 2022
Liang Hong
Executive Vice President, Staff Elected Director · since 2025
Yingwei Jiang
Executive Vice President · since 2022
Xiangke Xu
Senior Vice President, Secretary of the Board · since 2023
Yan Zhou
Senior Vice President · since 2023
Chengyi Chen
Chief Technology Officer · since 2025
Hao Hong
Chairman of the Board, Chief Executive Officer · since 2022
Ye Song
Non-Executive Director · since 2011
Ting Zhang
Non-Executive Director · since 2023
Independent Non-Executive Director · since 2024
Kar Chung Lee
Independent Non-Executive Director · since 2021
Xuejiao Sun
Independent Non-Executive Director · since 2023
Weikai Xie
Independent Non-Executive Director · since 2025
IPO date
Nov 18, 2016
Employees
9,719
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
洞庭三街6号
经济技术开发区
天津市, TJ 300457
CN
Other language
Asymchem Laboratories (Tianjin) Co., Ltd.

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT